OVERVIEW

The market for transdermal drug delivery systems is projected to rise at a CAGR of 4.3 percent over the forecast period. The market is primarily driven by the rising prevalence of chronic diseases, for which traditional drug delivery methods, such as oral medications, have lower potency due to hepatic first-pass metabolism. The study also contrasts the pre-COVID-19 and post-COVID-19 markets.

TABLE OF CONTENT

• 2 RESEARCH METHODOLOGY
  • 2.1 Research Data
    • 2.1.1 Secondary Data
      • 2.1.1.1 Key Data From Secondary Sources
    • 2.1.2 Primary Data
      • 2.1.2.1 Key Data From Primary Sources
      • 2.1.2.2 Key Industry Insights
      • 2.1.2.3 Breakdown of Primaries
  • 2.2 Market Size Estimation
    • 2.2.1 Bottom-Up Approach
    • 2.2.2 Top-Down Approach
  • 2.3 Market Breakdown and Data Triangulation
  • 2.4 Research Assumptions

• 3 Global Transdermal Drug Delivery System Market ? Executive Summary
  • 3.1 Market Revenue, Market Size and Key Trends by Company
  • 3.2 Key Trends by type of Application
  • 3.3 Key Trends segmented by Geography

• 4 Global Transdermal Drug Delivery System Market ? Comparative Analysis
  • 4.1 Product Benchmarking - Top 10 companies
  • 4.2 Top 5 Financials Analysis
  • 4.3 Market Value split by Top 10 companies
  • 4.4 Patent Analysis - Top 10 companies
  • 4.5 Pricing Analysis

• 5 Global Transdermal Drug Delivery System Market ? Industry Market Entry Scenario
  • 5.1 Regulatory Framework Overview
  • 5.2 New Business and Ease of Doing business index
  • 5.3 Case studies of successful ventures
  • 5.4 Customer Analysis ? Top 10 companies

• 6 Global Transdermal Drug Delivery System Market - Market Forces
  • 6.1 Introduction
  • 6.2 Market Dynamics
    • 6.2.1 Drivers
    • 6.2.2 Opportunities
    • 6.2.3 Challenges
  • 6.3 Porters Analysis of Market
    • 6.3.1 Bargaining power of suppliers
    • 6.3.2 Bargaining powers of customers
    • 6.3.3 Threat of new entrants
    • 6.3.4 Rivalry among existing players
    • 6.3.5 Threat of substitutes

• 7 Global Transdermal Drug Delivery System Market - Strategic Analysis
  • 7.1 Value Chain analysis
  • 7.2 Product Life Cycle
  • 7.3 Supplier and distributor analysis (Market share and product dealing strategies)

• 8 Global Transdermal Drug Delivery System Market ? By Type (Market Size ? & million/billion)
  • 8.1 Transdermal Patches
  • 8.2 Transdermal Semisolids

• 9 Global Transdermal Drug Delivery System Market - By Applications
  • 9.1 Pain Management
  • 9.2 Hormonal Applications
  • 9.3 Central Nervous System Disorders
  • 9.4 Cardiovascular Diseases
  • 9.5 Other

• 10 Global Transdermal Drug Delivery System Market - By End-User
  • 10.1 Home Care Settings
  • 10.2 Hospitals & Clinics

• 11 Global Transdermal Drug Delivery System Market ? By Geography (Market Size ? &

• • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 U.K
    • 11.3.2 Germany
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 South Korea
    • 11.4.5 Rest of APAC
  • 11.5 Rest of the World
    • 11.5.1 South America
    • 11.5.2 Middle East
    • 11.5.3 Africa

• 12 Global Transdermal Drug Delivery System Market ? Entropy
  • 12.1 New product launches
  • 12.2 M&A's, collaborations, JVs and partnerships

• 13 Global Transdermal Drug Delivery System Market Company Profile (Key Players)
  • 13.1 Market Share, Company Revenue, Products, M&A, Developments
  • 13.2 Hisamitsu Pharmaceutical Co., Inc.
  • 13.3 Mylan N.V.
  • 13.4 UCB S.A.
  • 13.5 Novartis AG
  • 13.6 Purdue Pharma L.P.
  • 13.7 Lavipharm
  • 13.8 Glaxosmithkline PLC
  • 13.9 Johnson & Johnson (J&J)
  • 13.10 Endo International, Inc.
  • 13.11 Boehringer Ingelheim International GmbH
  • 13.12 Company 11 & more

• 14 Global Transdermal Drug Delivery System Market - Appendix
  • 14.1 Sources
  • 14.2 Abbreviations